Kiniksa Pharmaceuticals International (KNSA) Accumulated Expenses (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Accumulated Expenses came in at $46.7 million in Q2 2026, up 29.95% YoY from $36.0 million in Q2 2025, and up 42.6% on a QoQ basis from $32.8 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Accumulated Expenses (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Accumulated Expenses data on file, last reported at $46.7 million in Q2 2026.
- Quarterly Accumulated Expenses rose 29.95% year-over-year to $46.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $46.7 million (up 29.95% YoY) and the FY2025 annual result came in at $42.0 million, up 29.87% from the prior year.
- Accumulated Expenses grew to $46.7 million in Q2 2026, from $32.8 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $46.7 million in Q2 2026 to a low of $20.9 million in Q1 2023.
- A 5-year average of $34.5 million and a median of $33.9 million in 2022 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2024 — Accumulated Expenses surged 114.12% — and 2025, when it sank 50.52%.
- Tracing KNSA's Accumulated Expenses over 5 years: stood at $30.1 million in 2022, then dropped by 7.92% to $27.7 million in 2023, then grew by 16.69% to $32.4 million in 2024, then climbed by 29.87% to $42.0 million in 2025, then rose by 11.21% to $46.7 million in 2026.
- The last three Accumulated Expenses figures came in at $46.7 million (Q2 2026), $32.8 million (Q1 2026), and $42.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.57 Bn | 220.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.73 Mn |
| Mar 31, 2026 | 32.77 Mn |
| Dec 31, 2025 | 42.02 Mn |
| Sep 30, 2025 | 30.94 Mn |
| Jun 30, 2025 | 35.96 Mn |
| Mar 31, 2025 | 22.13 Mn |
| Dec 31, 2024 | 32.36 Mn |
| Sep 30, 2024 | 40.38 Mn |
| Jun 30, 2024 | 33.37 Mn |
| Mar 31, 2024 | 44.72 Mn |
| Dec 31, 2023 | 27.73 Mn |
| Sep 30, 2023 | 41.15 Mn |
| Jun 30, 2023 | 35.32 Mn |
| Mar 31, 2023 | 20.89 Mn |
| Dec 31, 2022 | 30.11 Mn |
| Sep 30, 2022 | 30.87 Mn |
| Jun 30, 2022 | 34.50 Mn |
| Mar 31, 2022 | 38.89 Mn |
| Dec 31, 2021 | 38.03 Mn |
| Sep 30, 2021 | 28.53 Mn |